Actively Recruiting
Evaluating the Hscore and Diagnostic Markers for Lymphohistiocytic Hemophagocytosis in Adults in Intensive Care
Led by University Hospital, Strasbourg, France · Updated on 2026-01-15
100
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
This research focuses on patients with liver problems such as hepatocellular insufficiency and cirrhosis, who are at risk of serious fungal infections, especially in intensive care units. The study aims to assess how well the hscore, a diagnostic tool, works in these critical care patients for detecting lymphohistiocytic hemophagocytosis, a condition marked by immune system overactivity. This evaluation is important because current antifungal treatments like voriconazole can cause liver toxicity, while newer options like isavuconazole may be better tolerated but need more study in this context. The study is observational and will look back at patient data collected between January 1, 2014, and December 31, 2024, from intensive care patients at Hautepierre Hospital in Strasbourg. It does not involve any new treatments or interventions but rather analyzes existing clinical and biological information to determine the usefulness of the hscore and to identify the best markers for diagnosis. Participants will be adults admitted to intensive care who show at least three biological signs of hemophagocytic lymphohistiocytosis HLH, including high ferritin, elevated triglycerides, and low blood cell counts. Researchers will review these clinical signs and outcomes over up to 12 months to validate the hscores diagnostic value. The study will monitor these markers retrospectively without affecting patient care, with results helping to improve diagnosis in the future.
CONDITIONS
Brief Title
Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care
Research Team
A
Antonin HUGEROT, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here